Participants who have had electroconvulsive therapy (ECT) within 3 months of screening or who will have ECT at any time during the study.Participants who are pregnant or nursing.Participants must be able to understand the nature of the study and have given their informed consent.Participants must be considered reliable, have a level of understanding sufficient to perform all tests and examinations required by the protocol, and be willing to perform all study procedures.Participants must have evidence of prominent negative symptoms of schizophrenia (for example blunted affect, emotional withdrawal, or motor retardation).Disease symptoms must meet a certain range as assessed by the clinician.Participants must have been receiving monotherapy treatment for at least 3 months prior to study entry with one of 4 atypical antipsychotic medications (aripiprazole, olanzapine, risperidone, quetiapine).Number of Participants With Incidence of Potentially Clinically Significant (PCS) Change in Laboratory Values Any Time Post-Baseline - Fasting Triglycerides.PCS change in high-density lipoprotein (HDL) cholesterol: ≥40 mg/dL at baseline and <40 mg/dL post-baseline. PCS change in low-density lipoprotein (LDL) cholesterol: N to H <100 mg/dL at baseline and ≥160 mg/dL post-baseline B to H ≥100 mg/dL and <160 mg/dL at baseline and ≥160 mg/dL post-baseline N/B to H <160 mg/dL at baseline and ≥160 mg/dL post-baseline N to B/H <100 mg/dL at baseline, ≥100 mg/dL post-baseline. PCS change in total cholesterol: Normal (N) to High (H) <200 milligrams/deciliter (mg/dL) at baseline and ≥240 mg/dL post-baseline Borderline (B) to H ≥200 mg/dL and <240 mg/dL at baseline and ≥240 mg/dL post-baseline N/B to H <240 mg/dL at baseline and ≥240 mg/dL post-baseline N to B/H <200 mg/dL at baseline, ≥200 mg/dL post-baseline. PCS change in laboratory values were defined as a laboratory value which reached a predefined alert level at any time post-baseline. Change From Baseline in Standing Blood Pressure (BP).Neurological change from baseline was assessed using a 17-item neurological examination and defined as treatment-emergent tremor, nystagmus, increased reflexes, decreased reflexes, abnormal finger-nose test (Item 12 normal to abnormal), Romberg's sign (Item 13 absent to present), abnormal gait (Item 14 normal to abnormal), decreased muscle strength, myoclonic jerks. Change From Baseline in University of California at San Diego Performance-Based Skills Assessment-Brief Version (UPSA-B) Total Score.LS mean values are controlled for visit, pooled investigative site, treatment, standard of care (SOC) type, baseline positive symptom stratum, treatment*visit, baseline MCCB overall composite T-score, and baseline MCCB overall composite T-score*visit. The Mixed Model Repeated Measure (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. The MCCB overall composite T-score combines the individual scores of the 10 tests and scores them on a normative scale to derive a T-score, where the mean is 50 and a standard deviation is 10 for the MCCB overall composite T-score.

MCCB is an instrument that contains 10 tests to measure cognitive performance in 7 cognitive domains: speed processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition. Why Should I Register and Submit Results?.

Negative symptoms of schizophrenia